Effect of inotrope withdrawal on morbidity and mortality in patients with chronic heart failure: results of the vesnarinone trial withdrawal substudy. Vest Withdrawal Substudy Group.
作者信息
Soran O, Young J D, Holubkov R, Loftus S, Bourge R, Carson P, Jaski B, White B G, Feldman A M
机构信息
Cardiovascular Institute of the University of Pittsburgh Medical Center Health System, Pennsylvania, USA.
出版信息
J Card Fail. 1999 Sep;5(3):195-200; discussion 201-2. doi: 10.1016/s1071-9164(99)90003-9.
BACKGROUND
The use of inotropic agents in the therapy of patients with congestive heart failure (CHF) is controversial. One concern regarding inotropic therapy has been that drug withdrawal could be associated with a worsening of symptoms.
METHODS AND RESULTS
We took advantage of the discontinuation of the recent trial of vesnarinone in the therapy of CHF to assess the effects of withdrawal of the inotropic agent, vesnarinone, in patients with chronic CHF who had been randomized to receive either placebo or 30 or 60 mg of vesnarinone. Contrary to our initial hypothesis, withdrawal of vesnarinone did not impact on either morbidity or mortality over a period of 6 months.
CONCLUSION
Although these results suggest vesnarinone withdrawal is safe, the applicability of these results to other inotropic agents remains unclear.
Zotero 插件